SCHEMBL17906201

SCHEMBL17906201

Cc1c(C)n(-c2ccc(Br)cc2)c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.44
▸ ATM Q13315 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TSHR P16473 2/20 0.43
▸ HDAC6 Q9UBN7 2/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ HTT P42858 3/20 0.40
▸ RORC P51449 1/20 0.39
▸ PLA2G2A P14555 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ MAPT P10636 2/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ USP14 P54578 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ THRB P10828 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17906205 0.87 KDM4E (0.59) KDM4EATML3MBTL1HDAC6HTT
SCHEMBL18969703 0.85 KDM4E (0.47) KDM4EATML3MBTL1TSHRHDAC6
SCHEMBL11379057 0.85 KDM4E (0.61) KDM4EATML3MBTL1HTTRORC
SCHEMBL2758580 0.82 KDM4E (0.44) KDM4EATML3MBTL1TSHRHDAC6
SCHEMBL262160 0.81 KDM4E (0.67) KDM4EATML3MBTL1TSHRNPC1
SCHEMBL29400116 0.81 KDM4E (0.67) KDM4EATML3MBTL1TSHRNPC1
SCHEMBL22454015 0.79 KDM4E (0.41) KDM4EATML3MBTL1HDAC6HTT
SCHEMBL7140707 0.79 MAPT (0.54) KDM4EATML3MBTL1TSHRNPC1
SCHEMBL19931163 0.77 KDM4E (0.50) KDM4EATML3MBTL1TSHRNPC1
SCHEMBL5608517 0.76 KDM4E (0.41) KDM4EATML3MBTL1HTTPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9966537-B2 Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-08 — — US disclosed
US-9966537-B2 Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-08 — — US disclosed
US-9966537-B2 Compositions with 2,3-disubstituted indoles as charge transport materials, and display devices fabricated therefrom DOW GLOBAL TECHNOLOGIES LLC (US) 2018-05-08 — — US disclosed
US-20170373253-A1 Compositions with 2,3-Disubstituted Indoles as Charge Transport Materials, and Display Devices Fabricated Therefrom DOW GLOBAL TECHNOLOGIES LLC 2017-12-28 — — US disclosed
US-20170373253-A1 Compositions with 2,3-Disubstituted Indoles as Charge Transport Materials, and Display Devices Fabricated Therefrom DOW GLOBAL TECHNOLOGIES LLC 2017-12-28 — — US disclosed
CN-107406382-A Composition and the display device that is produced from it of 2,3 disubstituted indoles as charge transport materials 陶氏环球技术有限责任公司 2017-11-28 — — CN disclosed
WO-2016107459-A1 COMPOSITIONS WITH 2, 3-DISUBSTITUTED INDOLES AS CHARGE TRANSPORT MATERIALS, AND DISPLAY DEVICES FABRICATED THEREFROM DOW GLOBAL TECHNOLOGIES LLC (US) 2016-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170373253-A1 Compositions with 2,3-Disubstituted Indoles as Charge Transport Materials, and Display Devices Fabricated Therefrom IDO2, HTR3D, IDO1 KDM4E 3319/4885ATM 4371/4885L3MBTL1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback